Pharmaceutical Benefits Scheme - new and amended listings 1

On 1 February 2015, some new and amended listings were added to the Pharmaceutical Benefits Scheme (PBS).

This Budget measure is not subject to the passage of legislation.

Description of the measure

On 1 February 2015, some new and amended listings were added to the Pharmaceutical Benefits Scheme (PBS). These changes give eligible Australians and overseas visitors more affordable access to vital medicines. The changes are:

  • mifepristone and misoprostol – new listing for the termination of an intra-uterine pregnancy
  • chemotherapy drugs – reducing the authority level from Authority Required to Authority Required (streamlined) for a number of medicines including arsenic, bevacizumab, cabazitaxel, cetuximab, doxorubicin hydrochloride-pegylated liposomal, ipilimumab, panitumumab, pemetrexed and rituximab products

Questions and answers

Who is affected by this measure

Australians and eligible overseas visitors who receive PBS medicines. Health professionals including pharmacists, general practitioners, specialists and nurse practitioners will also be affected.

Who is eligible for this measure

The Schedule of Pharmaceutical Benefits has been updated to show the new and amended listings. Health professionals will decide if their patient is eligible under the restriction criteria listed in the Schedule of Pharmaceutical Benefits.

The date this measure will start and finish

This measure started on 1 February 2015 and is ongoing.

Page last updated: 15 March 2016

This information was printed Saturday 1 October 2016 from humanservices.gov.au/corporate/budget/budget-2015-16/budget-measures/health-matters-and-health-professionals/pharmaceutical-benefits-scheme-new-and-amended-listings-1 It may not include all of the relevant information on this topic. Please consider any relevant site notices at humanservices.gov.au/siteinformation when using this material.